CVR number 28312458
Industry 72.1100 Research and experimental development on biotechnology

EYE-D ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.2% 1.2% 1.2% 1.2% 1.2%  
Bankruptcy risk  8.8% 4.4% 13.4% 25.6% 23.7%  
Credit score (0-100)  29 47 16 2 3  
Credit rating  BB BBB BB B B  
Credit limit (kDKK)  0.0 0.0 0.0 -0.0 -0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  -202 2,008 -203 -388 -191  
EBITDA  -202 100 -1,060 -1,045 -726  
EBIT  -233 92.8 -1,078 -1,045 -726  
Pre-tax profit (PTP)  -267.4 87.6 -1,082.9 -1,063.7 -767.0  
Net earnings  -208.8 68.2 -758.6 -815.9 -588.8  
Pre-tax profit without non-rec. items  -267 87.6 -1,083 -1,064 -767  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  25.9 18.5 0.0 0.0 0.0  
Shareholders equity total  1,168 1,236 478 -338 -927  
Interest-bearing liabilities  0.0 0.0 0.0 328 16.7  
Balance sheet total (assets)  1,255 1,844 1,605 1,254 347  
Net Debt  -439 -762 -198 -137 -42.4  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -202 2,008 -203 -388 -191  
Gross profit growth  -245.9% 0.0% 0.0% -90.9% 50.8%  
Employees  0 3 2 1 1  
Employee growth %  0.0% 0.0% -33.3% -50.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,255 1,844 1,605 1,254 347  
Balance sheet change%  -57.4% 46.9% -13.0% -21.9% -72.3%  
Added value  -202.2 100.2 -1,059.6 -1,026.7 -726.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -61 -15 -37 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -2.0 1.0 -1.0 -2.0 -3.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  115.0% 4.6% 529.9% 269.1% 379.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -11.1% 6.0% -61.9% -64.4% -50.4%  
ROI %  -13.1% 7.8% -124.5% -255.7% -419.1%  
ROE %  -16.4% 5.7% -88.5% -94.2% -73.6%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  93.1% 67.0% 29.8% -21.2% -72.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  217.0% -760.3% 18.7% 13.1% 5.8%  
Gearing %  0.0% 0.0% 0.0% -97.0% -1.8%  
Net interest  0 0 0 0 0  
Financing costs %  6.9% 0.0% 0.0% 20.5% 25.9%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  34.5 2.9 1.3 0.8 0.3  
Current Ratio  34.5 2.9 1.3 0.8 0.3  
Cash and cash equivalent  438.7 761.7 197.8 465.1 59.0  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,086.9 1,121.3 362.2 -338.2 -927.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 33 -530 -1,027 -726  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 33 -530 -1,045 -726  
EBIT / employee  0 31 -539 -1,045 -726  
Net earnings / employee  0 23 -379 -816 -589